Added to YB: 2025-08-26
Pitch date: 2025-08-21
CRNX [bullish]
Crinetics Pharmaceuticals, Inc.
+47.7%
current return
Author Info
No bio for this author
Company Info
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Market Cap
$4.5B
Pitch Price
$29.79
Price Target
40.00 (-9%)
Dividend
N/A
EV/EBITDA
-7.38
P/E
-9.62
EV/Sales
2.2K
Sector
Pharmaceuticals
Category
growth
New long pitch - CRNX
CRNX: Rare endocrinology biotech w/ $1.2B cash runway to 2029. Lead drug Paltu Sept PDUFA for acromegaly, superior to current SOC w/ 83% IGF-1 control & $70-90K pricing. Atu targets CAH/Cushing's w/ ODD giving confidence on liver tox concerns. 4 IND filings 2025 expanding pipeline. $2B EV vs $1B+ peak sales potential. PT $40 short-term.
Read full article (5 min)